2026· International Journal of Medicine in Developing Countries· pp. 1· 0 citations
TL;DR
Biologic therapies targeting IgE, IL-5/IL-5Rα, and TSLP produce clinically meaningful, statistically significant improvements in nasal polyp size and sinonasal quality of life compared with placebo in patients with CRSwNP, although the magnitude of effect varies substantially by mechanism and population.
Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous, type 2-inflammation-driven disease of the sinonasal mucosa that is frequently refractory to intranasal and systemic corticosteroids and often recurs after endoscopic sinus surgery. Biologic agents targeting distinct upstream and downstream type 2 inflammatory mediators have been evaluated in phase 3 randomized controlled trials (RCTs) as add-on therapy to standard of care. This study aimed to systematically review and meta-analyze randomized, placebo-controlled trials of biologic therapies for CRSwNP, and to quantify their effect on nasal polyp size, sinonasal symptom burden, and the need for surgery or systemic corticosteroids. Databases were searched from inception to 15 August 2026, together with ClinicalTrials.gov and the WHO ICTRP. Five trial comparisons from four publications (62â"413 randomized patients per trial) had verified extractable data and were pooled quantitatively. All five reported statistically significant improvement in total NPS versus placebo at their respective primary endpoints (24â"52 weeks); the pooled random-effects mean/median difference was â'1.02 points (95% CI â'1.64 to â'0.41; I² ≤ 92.8%). SNOT-22 total score also improved across trials (pooled difference â'16.10 points, 95% CI â'23.57 to â'8.62; I² ≤ 87.4%), although the effect in OSTRO (benralizumab) did not reach statistical significance. Biologic therapies targeting IgE, IL-5/IL-5Rα, and TSLP produce clinically meaningful, statistically significant improvements in nasal polyp size and sinonasal quality of life compared with placebo in patients with CRSwNP, although the magnitude of effect varies substantially by mechanism and population, and cross-trial pooling should be interpreted cautiously given the very high statistical heterogeneity.
The observed trend toward enhanced benefit in T2-high patients supports the potential for endotype-directed therapy and underscores the need for larger studies to evaluate the role of T2-targeted biologics in CRSsNP management.
J. Tversky, Andrew P. Lane, John T. Schroeder et al.· Journal of Allergy and Clini...· 0 citations
OBJECTIVE
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, effectively reduced polyp size in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Tezepelumab also reduced the need for nasal polyp surgery and systemic corticosteroids (SCS) in the phase 3 WAYPOINT study across 10 countri...
N. Otori, Daiju Sakurai, Genki Iwai et al.· Auris, nasus, larynx· 0 citations
Objectives: Nasal polyps are present in a substantial proportion of patients with chronic rhinosinusitis (CRSwNP) and are driven, in most Western populations, by type 2 inflammation. Conventional treatment with corticosteroids and endoscopic sinus surgery frequently fails to provide durable disease control, particularl...
A. Osamah, Abdul-Razzaq Al-Itbi, Mohammed Hasan et al.· International Journal of Dru...· 0 citations
Background Biologic therapies have transformed management of severe chronic rhinosinusitis with nasal polyps (CRSwNP), but response variability persists. Baseline biomarkers may identify patients most likely to benefit, yet no marker is validated for routine clinical use. This systematic review evaluated baseline bioma...
Omair Al Hussain· Frontiers in Medicine· 0 citations
Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is defined by high postoperative recurrence rates. While standard therapies target inflammation, the crucial role of mucosal edema secondary to epithelial ion transport dysregulation offers a new therapeutic target. This systematic review aims to criticall...
Felipe Schulz· RCMOS - Revista Científica M...· 0 citations
Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic airway disease characterized mainly by type 2 inflammation, which seriously impairs patients' quality of life and imposes a huge economic burden. Traditional treatments cannot eradicate underlying immune disorders, leading to high postoperative r...
B. Huang, Yue Xu, Ye Tian et al.· Frontiers in Allergy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.